Focus on ERBB2

Pharmacogenomics

Volumn 9, Issue 7, 2008, Pages 825-828

  Benusiglio, Patrick R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN P; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN 1; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CELL DIVISION; DRUG BINDING; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; PHARMACOGENOMICS; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; BIOSYNTHESIS; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NOTE; PROTEIN BINDING; PROTO ONCOGENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; PROTEIN BINDING; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 49949108923     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.7.825     Document Type: Article

References (43)

1. Al-Kuraya K, Schraml P, Torhorst J et al.: Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64, 8534-8540 (2004).
2. Arpino G, Green SJ, Allred DC et al.: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res. 10, 5670-5676 (2004).
3. Callagy G, Pharoah P, Chin SF et al.: Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol. 205, 388-396 (2005).
4. Gullick WJ, Love SB, Wright C et al.: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer 63, 434-438 (1991).
5. Heintz NH, Leslie KO, Rogers LA, Howard PL: Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. Arch. Pathol. Lab. Med. 114, 160-163 (1990).
6. Hoff ER, Tubbs RR, Myles JL, Procop GW: HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am. J Clin. Pathol. 117, 916-921 (2002).
7. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer 79, 1220-1226 (1999).
8. Konecny G, Pauletti G, Pegram M et al.: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl Cancer Inst. 95, 142-153 (2003).
9. Press MF, Bernstein L, Thomas PA et al.: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15, 2894-2904 (1997).
10. Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene 22, 6570-6578 (2003).
11. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. Med. 344, 783-792 (2001).
12. Geyer CE, Forster J, Lindquist D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
13. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev. Mol. Cell Biol. 2, 127-137 (2001).
14. Penuel E, Schaefer G, Akita RW. Sliwkowski MX: Structural requirements for ErbB2 transactivation. Semin. Oncol. 28, 36-42 (2001).
15. Tzahar E, Waterman H, Chen X et al.: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 16, 5276-5287 (1996).
16. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA: Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell Biol. 8, 5570-5574 (1988).
17. Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657 (1986).
18. Papewalis J, Nikitin AY, Rajewsky MF: G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res. 19, 5452 (1991).
19. Fleishman SJ, Schlessinger J, Ben-Tai N: A putative molecular-activation switch in the transmembrane domain of erbB2. Proc. Natl Acad. Sci. USA 99, 15937-15940 (2002).
20. Xie D, Shu XO, Deng Z et al.: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl. Cancer Inst. 92, 412-417 (2000).
21. Montgomery KG, Gertig DM, Baxter SW et al.: The HER2 1655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol. Biomarkers Prev. 12, 1109-1111 (2003).
22. Akisik E, Dalay N: Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk, Exp. Mol. Pathol. 76, 260-263 (2004).
23. An HJ, Kim NK, Oh D et al.: Her2 V655 genotype and breast cancer progression in Korean women. Pathol. Int. 55, 48-52 (2005).
24. Baxter SW, Campbell IG: Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst. 93, 557-559 (2001).
25. Hishida A, Hamajima N, Iwata, H et al.: Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst. 94, 1807-1808 (2002).
26. Kalemi TG, Lambropoulos AF, Gueorguiev M et al.: The association of p53 mutations and p53 coclon 72, Her 2 cocion 655 and MTHFR C677T polymorphisms with breast cancer in northern Greece. Cancer Lett. 222, 57-65 (2005).
27. Kamali-Sarvestani E, Talei AR, Merat A: Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett. 215, 83-87 (2004).
28. Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A: Distribution of HER2 (V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett. 173, 37-41 (2001).
29. McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE: Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res. 61, 8393-8394 (2001).
30. Millikan R, Eaton A, Worley K et al.: HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res. Treat. 79, 355-364 (2003).
31. Wang-Gohrke S, Chang-Claude J: Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst. 93, 1657-1659 (2001).
32. Frank B, Hemminki K, Wirtenberger M et al.: The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 26, 643-647 (2005).
33. Nelson SE, Gould MN, Hampton JM, Trentham-Dietz A: A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res. 7, R357-R364 (2005).
34. Benusiglio PR, Pharoah PD, Smith PL et al.: HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br. J. Cancer. 95, 1689-1695 (2006).
35. Eínarsdóttir K, Rosenberg LU, Humphreys K et al.: Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res. 8, R67-R78 (2006).
36. Cox DG, Hankinson SE, Hunter DJ: The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet. Genomics 15, 447-450 (2005).
37. Ma PC, Zhang X, Wang ZJ: High-throughput mutational analysis of the human cancer genome. Pharmacogenomics 7, 597-612 (2006).
38. Katz DA: From bench to bedside: a diagnostics framework for pharmacogenetics research. Mol. Genet. Metab. 77, 57-60 (2002).
39. Tsongalis GJ, Cartun RW, Ricci A Jr: Gene amplification as means for determining therapeutic strategies in human cancers. Clin. Chem. Lab. Med. 38, 837-839 (2000).
40. Han W, Kang D, Lee JE: A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin. Cancer Res. 11, 4775-4778 (2005).
41. Wood ER, Truesdale AT, McDonald OB et al.: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
42. Spector N, Xia W, El-Hariry I, Yarden Y, Bacus S: HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 9, R205-R212 (2007).
43. Burris HA 3rd, Hurwitz HI, Dees EC: Phase I Safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305-5313 (2005).